Metastatic malignant solitary fibrous tumour to the infra-temporal fossa

• Published in: International journal of oral and maxillofacial surgery 2003-12, Vol.32 (6), p.659-661
• Main Authors: Suhr, M., Gottschalk, J., Kreusch, Th
• Format: Article
• Language: English
• Subjects: Antigens, CD34 - analysis; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CD34; Dentistry; Doxorubicin - administration & dosage; Female; Humans; Ifosfamide - administration & dosage; Immunohistochemistry; malignant solitary fibrous tumour; metastatic; Middle Aged; Neoplasms, Fibrous Tissue - classification; Neoplasms, Fibrous Tissue - drug therapy; Neoplasms, Fibrous Tissue - secondary; Neoplasms, Fibrous Tissue - surgery; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - pathology; Skull Base Neoplasms - diagnosis; Skull Base Neoplasms - drug therapy; Skull Base Neoplasms - secondary; Skull Base Neoplasms - surgery; Terminology as Topic; vimentin
• ISSN: 0901-5027; 1399-0020
• DOI: 10.1054/ijom.2003.0393

Malignant solitary fibrous tumours (MSFTs) are rare tumours of fibrous origin, which can occur at all anatomical sites and represent 20% of solitary fibrous tumours. Fine-needle aspiration cytology is not able to distinguish benign from malignant disease, and sufficient tissue has to be obtained for accurate histological diagnosis to be made. Lesions >10cm in diameter and incomplete resection or non-resectability are predictive factors for poor long-term survival. We present a 57-year-old patient with a presumably metastatic MSFT from the peritoneal cavity to the skull-base who is in a stable state 17 months after surgical debulking of the skull-base and removal of the peritoneal lesion, followed by post-operative chemotherapy. We suggest the terminology metastatic malignant solitary fibrous tumour for a description of this disease.